Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).

Keskin, S.; YILDIZ, İBRAHİM; AYDOĞMUŞ ŞEN, Fatma; AYDOĞAN, Fatih; Kilic, LEYLA; EKENEL, Meltem; Saglam, S.; ŞAKAR, Burak; Disci, R.; Aykan, F.

doi:10.1007/s12094-012-0942-8

Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).

Keskin S., YILDIZ İ., AYDOĞMUŞ ŞEN F., AYDOĞAN F., Kilic L., EKENEL M., ...Daha Fazla

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, cilt.15, sa.5, ss.403-8, 2013 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 15 Sayı: 5
Basım Tarihi: 2013
Doi Numarası: 10.1007/s12094-012-0942-8
Dergi Adı: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.403-8
Anahtar Kelimeler: Modified DCF, Advanced gastric cancer, Efficacy, Adverse effect, Survival, SINGLE-INSTITUTION EXPERIENCE, PHASE-II, 1ST-LINE THERAPY, ESOPHAGEAL CANCER, WEEKLY DOCETAXEL, SUPPORTIVE CARE, PLUS CISPLATIN, FLUOROURACIL, 5-FLUOROURACIL, TRIAL
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

The aim of this retrospective study (from January 2007 to December 2011) was to investigate the efficacy and tolerability of mDCF schedule for chemotherapy-na < ve AGC patients.